Skip to Main Content


Amin Nassar, MD

Clinical Fellow

Research Summary

Dr. Nassar's research work has emanated in >40 original articles. His work aims at identifying genomic biomarkers across ancestral populations with cancer.

Extensive Research Description

  • Along with his colleagues, Dr. Nassar showed in a study published in "Cancer Cell" that tumor-only sequencing overestimates TMB especially in non-Europeans and developed a methodology to recalibrate TMB calculation by ancestry. They also showed that TMB may not be a biomarker predictive of clinical benefit in non-Europeans.
  • Dr. Nassar described the prevalence of KRASG12C mutations across sex, race, and cancer types. This work was published in the “The New England Journal of Medicine”.
  • Dr. Nassar found that genomic alterations in CDKN2A portend worse clinical outcomes in patients with urothelial carcinoma treated with immunotherapy drugs.
  • Dr. Nassar developed a clinical and genetic model that incorporates three different factors (neutrophil-to-lymphocyte ratio, visceral metastasis and TMB) and can predict benefit to immune checkpoint inhibitors.
  • Along with his colleagues, Dr. Nassar identified differences in the germline landscape among continental ancestries with renal cell carcinoma.


Research Interests

Genetics, Population; Biomarkers, Tumor; Epigenomics

Selected Publications